Molbio Diagnostics Limited, a leader in point-of-care (POC) molecular diagnostics, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, headquartered in Verna, South Goa, operates the proprietary 'Truenat' platform, which delivers accurate diagnostic results within approximately 60 minutes using portable, battery-operated PCR technology. The proposed IPO involves a fresh issue of ₹177.81 crore, aimed at funding significant capital expenditure for R&D consolidation and manufacturing automation. With the IPO scheduled to open on 10-Aug-2026, investors are closely monitoring the financial performance and risk factors outlined in the filing.

Company Overview

Molbio Diagnostics was founded in 2000 and specializes in developing accurate, rapid, and cost-effective healthcare technologies for diagnosing infectious and non-communicable diseases. Its flagship product, the Truenat platform, comprises the Trueprep nucleic acid extraction device and the Truelab Analyzer. As of March 31, 2026, the platform supports 43 assays for 30 diseases, including tuberculosis, COVID-19, Hepatitis B & C, HIV, and HPV.

The company operates in an oligopolistic market with high entry barriers, having required 13 years of R&D to obtain ICMR certification. Molbio holds a strong position in tuberculosis diagnostics, which constituted 70.20% of FY2026 revenues. The global Point-of-Care Testing (POCT) market is valued at USD 29.3 billion and projected to reach USD 67.1 billion by 2030, growing at a CAGR of 17.9% between 2025–2030.

Key management includes CEO Sriram Natarajan (35 years experience) and CTO Dr. Chandrasekhar Bhaskaran Nair (34 years experience). Recent strategic acquisitions include a 65.47% stake in Prognosys Medical Systems (March 2023) for radiology capabilities and a 60.00% stake in OptraScan INC (October 2024) for digital pathology solutions.

Offer Details

The IPO structure consists solely of a fresh issue, with no Offer for Sale (OFS) component disclosed in the DRHP data provided. The total identified capital expenditure from the proceeds is ₹177.81 crore.

Objects of the Issue

The proceeds will be utilized for the following purposes:

1. R&D Facility and Center of Excellence: ₹105.53 crore for a ~150,000 sq. ft. built-up area to consolidate R&D functions operated by wholly-owned subsidiary Bigtec.
2. Manufacturing Capex: ₹72.28 crore for purchase of plant, machinery, and equipment (including automatic precision liquid micro-volume filling machines) for Goa Unit I, Goa Unit II, and Visakhapatnam Unit.
3. General Corporate Purposes: Amount not specified, subject to not exceeding 25% of Gross Proceeds.

IPO Timeline

Price band, lot size, and reservation categories are not available in the current DRHP data.

Financial Highlights

Molbio Diagnostics has demonstrated strong revenue growth over the past three years. Revenue from operations grew at a CAGR of ~31.36% from ₹836.56 crore in FY2024 to ₹1,445.69 crore in FY2026. Profit After Tax (PAT) grew at a CAGR of ~40.13% over the same period.

Key Financial Metrics (Standalone)

Note: PAT margin contracted from 13.48% in FY2025 to 11.28% in FY2026 despite revenue growth. Operating cash flow declined sharply from ₹287.10 crore in FY2025 to ₹50.39 crore in FY2026.

Risk Factors

Investors should note several material risks highlighted in the DRHP:

1. Heavy Dependence on Government/Aid Agencies: 84.56% of FY2026 revenue was derived from Indian central/state governments and international aid agencies. Policy changes or budget cuts could materially impact revenue.
2. Concentration in TB Diagnostics: Tuberculosis diagnostic test kits contributed 70.20% of FY2026 revenues, creating vulnerability to policy shifts or alternative diagnostic methods.
3. Customer Concentration: Top 10 customers accounted for 83.26% of FY2026 revenues.
4. Working Capital and Debt Risks: Total outstanding borrowings stood at ₹4,225.01 million as of May 31, 2026. Non-current liabilities surged ~436.86% YoY. Working capital days were 166 in FY2026.
5. Subsidiary Losses: Key subsidiaries, including OptraScan INC (losses of ₹111.42 million in FY2026), have incurred losses.
6. Capacity Under-utilization: Truenat Device capacity utilization declined to 42.30% in FY2026 from 58.89% in FY2025.
7. Leasehold Dependencies: All manufacturing facilities, R&D units, and corporate offices are on leased land; no owned property.

Valuation & Peer Comparison

The price band for the IPO has not been disclosed in the DRHP data provided. Therefore, pre-issue P/E, post-issue P/E, and Price-to-Book ratios are not available. Peer comparison data with specific competitor metrics is also not available in the provided text. Investors should evaluate the issue against the FY2026 PAT of ₹164.14 crore and book value of ₹1,308.78 crore once the price band is announced.

Bottom Line

Molbio Diagnostics presents a profile of strong top-line growth and a proprietary technology platform in a high-growth market. However, the DRHP highlights significant concentration risks, particularly regarding government customers and tuberculosis diagnostics. Additionally, rising debt levels, declining operating cash flow, and subsidiary losses warrant careful scrutiny. The final investment decision will depend heavily on the valuation implied by the yet-to-be-announced price band.

Molbio Diagnostics Limited, a leader in point-of-care molecular diagnostics, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, headquartered in Goa, is known for its proprietary 'Truenat' platform which delivers rapid diagnostic results in resource-limited settings. The IPO is scheduled to open on 10-Aug-2026 and close on 12-Aug-2026, with listing expected on 17-Aug-2026. While the issue size and price band are yet to be finalized, the filing provides deep insights into the company's strong financial growth and strategic positioning in the global diagnostics market.

Company Overview

Molbio Diagnostics operates as a point-of-care diagnostics company focusing on molecular testing for infectious and non-communicable diseases. Its flagship product, the Truenat platform, comprises the Trueprep (nucleic acid extraction device) and Truelab Analyzer (portable PCR analyzer). This closed-system design ensures recurring revenue through test kit sales.

Key operational highlights include:

• Disease Coverage: Tests for 30 diseases with 43 assays as of March 31, 2026, including Tuberculosis (TB), COVID-19, Hepatitis B & C, HIV, and HPV.
• Manufacturing: Facilities located in Goa (Unit I & II) and Visakhapatnam. Note that all manufacturing facilities and offices are on leased land.
• Market Position: Operates in an oligopolistic market with high entry barriers, requiring 13 years of R&D for ICMR certification.
• Subsidiaries: Holds stakes in Bigtec (100%, R&D), Prognosys Medical Systems (65.47%, Radiology), and OptraScan INC (60.00%, Digital Pathology).

Offer Details

The specific issue size, price band, and lot size are not available in the DRHP and will be disclosed in the final Red Herring Prospectus (RHP). However, the timeline and objects of the issue are defined:

Objects of the Issue: The proceeds will primarily fund capital expenditure:

1. R&D Facility: ₹105.53 Crores for a Center of Excellence operated by Bigtec (~150,000 sq. ft.).
2. Automation: ₹72.28 Crores for plant, machinery, and equipment at Goa and Visakhapatnam units.
3. General Corporate Purposes: Up to 25% of gross proceeds.

Total identified use of proceeds is ₹177.81 Crores.

Financial Highlights

Molbio Diagnostics has demonstrated robust top-line growth over the past three years. Revenue from operations grew at a 3-year CAGR of approximately 31.40%.

While revenue surged by 41.68% YoY in FY2026, PAT growth decelerated to 18.44% YoY, leading to margin compression. Operating cash flow declined sharply from ₹287.10 Cr in FY2025 to ₹50.39 Cr in FY2026, despite strong revenue performance.

Risk Factors

Investors should note several material risks highlighted in the DRHP:

1. High Government Dependency: 84.56% of FY2026 revenue was derived from Indian central/state governments and international aid agencies. Policy changes could significantly impact sales.
2. TB Test Kit Concentration: Tuberculosis diagnostic kits contributed 70.20% of revenue in FY2026, an increase from 62.40% in FY2024. Decline in TB kit demand poses a significant risk.
3. Customer Concentration: The top 10 customers accounted for 83.26% of revenue in FY2026.
4. Working Capital & Debt: Total outstanding borrowings stood at ₹4,225.01 million as of May 31, 2026. Non-current liabilities surged by 436.86% YoY in FY2026.
5. Subsidiary Losses: Key subsidiaries, including OptraScan INC (loss of ₹111.42 million in FY2026), have incurred losses.

Valuation & Peer Comparison

Peer comparison data and valuation multiples (P/E, P/B) are not available as the price band has not been announced. The global Point-of-Care Testing (POCT) market is projected to grow from USD 29.3 billion in 2025 to USD 67.1 billion by 2030 at a CAGR of 17.90%, providing a large addressable market for Molbio.

Bottom Line

Molbio Diagnostics presents a compelling growth story with a proprietary technology platform and strong revenue expansion. However, investors must weigh this against high concentration risks in government funding and TB tests, along with margin compression and rising debt levels. The final valuation will depend on the price band announced in the RHP.